{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T08:00:59Z","timestamp":1794211259950,"version":"4.8.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite clear guidelines recommendations, most patients with heart failure and reduced ejection\u2013fraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate characteristics and for treatment-indication-bias corrected clinical outcome of patients with HFrEF that did not reach recommended treatment doses of ACE-inhibitors\/Angiotensin receptor blockers (ARBs) and\/or beta-blockers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>BIOSTAT-CHF was specifically designed to study uptitration of ACE-inhibitors\/ARBs and\/or beta-blockers in 2516 heart failure patients from 69 centres in 11 European countries who were selected if they were suboptimally treated while initiation or uptitration was anticipated and encouraged. Patients who died during the uptitration period (n\u2009=\u2009151) and patients with a LVEF\u2009&amp;gt;\u200940% (n\u2009=\u2009242) were excluded. Median follow up was 21 months. We studied 2100 HFrEF patients (76% male; mean age 68\u2009\u00b112), of which 22% achieved the recommended treatment dose for ACE-inhibitor\/ARB and 12% of beta-blocker. There were marked differences between European countries. Reaching\u2009&amp;lt;50% of the recommended ACE-inhibitor\/ARB and beta-blocker dose was associated with an increased risk of death and\/or heart failure hospitalization. Patients reaching 50\u201399% of the recommended ACE-inhibitor\/ARB and\/or beta-blocker dose had comparable risk of death and\/or heart failure hospitalization to those reaching\u2009\u2265100%. Patients not reaching recommended dose because of symptoms, side effects and non-cardiac organ dysfunction had the highest mortality rate (for ACE-inhibitor\/ARB: HR 1.72; 95% CI 1.43\u20132.01; for beta-blocker: HR 1.70; 95% CI 1.36\u20132.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with HFrEF who were treated with less than 50% of recommended dose of ACE-inhibitors\/ARBs and beta-blockers seemed to have a greater risk of death and\/or heart failure hospitalization compared with patients reaching\u2009\u2265100%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehx026","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T08:27:49Z","timestamp":1485764869000},"page":"1883-1890","source":"Crossref","is-referenced-by-count":366,"title":["Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study"],"prefix":"10.1093","volume":"38","author":[{"given":"W.","family":"Ouwerkerk","sequence":"first","affiliation":[{"name":"1Department of Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Voors","sequence":"additional","affiliation":[{"name":"2Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Anker","sequence":"additional","affiliation":[{"name":"3Innovative Clinical Trials, Department of Cardiology & Pneumology, University Medical Center G\u00f6ttingen (UMG), Robert-Koch-Stra\u00dfe 40 37075, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Cleland","sequence":"additional","affiliation":[{"name":"4National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, Sydney St, Chelsea, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dickstein","sequence":"additional","affiliation":[{"name":"5University of Bergen, 5007 Bergen, Norway"},{"name":"5University of Bergen, 5007 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Filippatos","sequence":"additional","affiliation":[{"name":"6Stavanger University Hospital, Gerd-Ragna Bloch Thorsens Gate 8, 4011 Stavanger, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van der Harst","sequence":"additional","affiliation":[{"name":"2Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.L.","family":"Hillege","sequence":"additional","affiliation":[{"name":"2Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.C.","family":"Lang","sequence":"additional","affiliation":[{"name":"7National and Kapodistrian University of Athens, School of Medicine & Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, 1, Rimini Str, Haidari, 124 62 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"ter Maaten","sequence":"additional","affiliation":[{"name":"2Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Ng","sequence":"additional","affiliation":[{"name":"8School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"10Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital, 50-981 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J","family":"Samani","sequence":"additional","affiliation":[{"name":"8School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, DD1 9SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"2Department of Cardiology, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zannad","sequence":"additional","affiliation":[{"name":"10Department of Heart Diseases, Wroclaw Medical University, Poland and Cardiology Department, Military Hospital, 50-981 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Metra","sequence":"additional","affiliation":[{"name":"12Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health; University of Brescia, Piazza del Mercato, 15, 25121 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Zwinderman","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,11]]},"reference":[{"key":"2022102614533968100_ehx026-B1","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"10","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2022102614533968100_ehx026-B2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure","volume":"325","author":"The SOLVD Investigators*","year":"1991","journal-title":"N Engl J Med"},{"key":"2022102614533968100_ehx026-B3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA J Am Med Assoc"},{"key":"2022102614533968100_ehx026-B4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2022102614533968100_ehx026-B5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"2022102614533968100_ehx026-B6","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of Carvedilol on Survival in Severe Chronic Heart Failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"2022102614533968100_ehx026-B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"2022102614533968100_ehx026-B8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2022102614533968100_ehx026-B9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"2022102614533968100_ehx026-B10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of Enalapril on Mortality in Severe Congestive Heart Failure","volume":"316","author":"The CONSENSUS Trial Study Group*","year":"1987","journal-title":"N Engl J Med"},{"key":"2022102614533968100_ehx026-B11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors","volume":"327","author":"The SOLVD Investigators*","year":"1992","journal-title":"N Engl J Med"},{"key":"2022102614533968100_ehx026-B12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A Comparison of Enalapril with Hydralazine\u2013Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"2022102614533968100_ehx026-B13","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2022102614533968100_ehx026-B14","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"key":"2022102614533968100_ehx026-B15","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet Elsevier Ltd"},{"issue":"Suppl 2","key":"2022102614533968100_ehx026-B16","first-page":"ii5","article-title":"Contemporary management of heart failure in clinical practice","volume":"88","author":"Cleland","year":"2002","journal-title":"Heart"},{"key":"2022102614533968100_ehx026-B17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur Heart J"},{"key":"2022102614533968100_ehx026-B18","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.ijcard.2012.06.116","article-title":"Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study","volume":"167","author":"Kalra","year":"2013","journal-title":"Int J Cardiol Elsevier Ireland Ltd"},{"key":"2022102614533968100_ehx026-B19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2022102614533968100_ehx026-B20","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"2022102614533968100_ehx026-B21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2307\/2530022","article-title":"Efficient Screening of Nonnormal Regression Models","volume":"34","author":"Lawless","year":"1978","journal-title":"Biometrics"},{"key":"2022102614533968100_ehx026-B22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/sim.4780080702","article-title":"Bootstrap investigation of the stability of a Cox regression model","volume":"8","author":"Altman","year":"1989","journal-title":"Stat Med"},{"key":"2022102614533968100_ehx026-B23","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies","author":"Harrell","year":"2015","edition":"2nd ed"},{"key":"2022102614533968100_ehx026-B24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1982.10477788","article-title":"An Analysis of Transformations Revisited, Rebutted","volume":"77","author":"Box","year":"1982","journal-title":"J Am Stat Assoc"},{"key":"2022102614533968100_ehx026-B25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hup.2528","article-title":"A simple method for optimising transformation of non-parametric data: an illustration by reference to cortisol assays","volume":"31","author":"Clark","year":"2016","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2022102614533968100_ehx026-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"mice\u202f: Multivariate Imputation by Chained Equations in R","volume":"45","author":"Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"2022102614533968100_ehx026-B27","article-title":"Reducing Selection Bias with Propensity Scores","volume":"18","author":"Adelson","year":"2013","journal-title":"Pract Assessment, Res Eval"},{"key":"2022102614533968100_ehx026-B28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/01621459.1986.10478354","article-title":"Statistics and causal inference","volume":"81","author":"Holland","year":"1986","journal-title":"J Am Stat Assoc"},{"key":"2022102614533968100_ehx026-B29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1198\/016214504000001880","article-title":"Causal Inference Using Potential Outcomes","volume":"100","author":"Rubin","year":"2005","journal-title":"J Am Stat Assoc"},{"key":"2022102614533968100_ehx026-B30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/01621459.1994.10476818","article-title":"Estimation of Regression Coefficients When Some Regressors are not Always Observed","volume":"89","author":"Robins","year":"1994","journal-title":"J Am Stat Assoc"},{"key":"2022102614533968100_ehx026-B31","doi-asserted-by":"crossref","DOI":"10.1515\/em-2014-0021","article-title":"Doubly Robust Estimation with the R Package drgee","volume":"4","author":"Zetterqvist","year":"2015","journal-title":"Epidemiol Method"},{"key":"2022102614533968100_ehx026-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v043.i13","article-title":"ipw: An R Package for Inverse Probability Weighting","volume":"43","author":"Wal","year":"2011","journal-title":"J Stat Softw"},{"key":"2022102614533968100_ehx026-B33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1214\/ss\/1038425655","article-title":"Flexible smoothing with B -splines and penalties","volume":"11","author":"Eilers","year":"1996","journal-title":"Stat Sci"},{"key":"2022102614533968100_ehx026-B34","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"2022102614533968100_ehx026-B35","doi-asserted-by":"crossref","first-page":"f55","DOI":"10.1136\/bmj.f55","article-title":"Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"key":"2022102614533968100_ehx026-B36","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ehj.2004.05.022","article-title":"Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR\/XL in elderly patients with heart failure","volume":"25","author":"Deedwania","year":"2004","journal-title":"Eur Heart J"},{"key":"2022102614533968100_ehx026-B37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2022102614533968100_ehx026-B38","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2022102614533968100_ehx026-B39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurjhf\/hfr020","article-title":"Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial","volume":"13","author":"D\u00fcngen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2022102614533968100_ehx026-B40","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/eurjhf\/hfq169","article-title":"Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure--SIGNAL-HF (swedish intervention study--guidelines and NT-proBNP anaLysis in heart failure)","volume":"12","author":"Persson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2022102614533968100_ehx026-B41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/CIRCHEARTFAILURE.113.000929","article-title":"Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction","volume":"7","author":"Brenyo","year":"2014","journal-title":"Circ Hear Fail"},{"key":"2022102614533968100_ehx026-B42","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.jacc.2006.11.042","article-title":"Inverse Relationship of Blood Pressure Levels to Sudden Cardiac Mortality and Benefit of the Implantable Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction","volume":"49","author":"Goldenberg","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022102614533968100_ehx026-B43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.108.825059","article-title":"Reverse Epidemiology in Systolic and Nonsystolic Heart Failure: Cumulative Prognostic Benefit of Classical Cardiovascular Risk Factors","volume":"2","author":"G\u00fcder","year":"2009","journal-title":"Circ Hear Fail"},{"key":"2022102614533968100_ehx026-B44","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and Prognostic Significance of Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy Receiving Tailored Medical Treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol Elsevier Inc"},{"key":"2022102614533968100_ehx026-B45","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ejhf.252","article-title":"Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling","volume":"17","author":"G\u00fcder","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2022102614533968100_ehx026-B46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/009127000004000102","article-title":"Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure","volume":"40","author":"Sokol","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"2022102614533968100_ehx026-B47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0031-1284434","article-title":"Liver Abnormalities in Cardiac Diseases and Heart Failure","volume":"20","author":"Alvarez","year":"2011","journal-title":"Int J Angiol"},{"key":"2022102614533968100_ehx026-B48","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2022102614533968100_ehx026-B49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/euhj.1997.0839","article-title":"Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison","volume":"19","author":"The NETWORK investigators","year":"1998","journal-title":"Eur Heart J"},{"key":"2022102614533968100_ehx026-B50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.161.2.165","article-title":"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival","volume":"161","author":"Massie","year":"2001","journal-title":"Arch Intern Med"},{"key":"2022102614533968100_ehx026-B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2143\/AC.55.1.2005711","article-title":"Long-term effects of clinical outcome with low and high dose in the captopril in heart insufficient patients study (CHIPS)","volume":"55","author":"Clement","year":"2000","journal-title":"Acta Cardiol"},{"key":"2022102614533968100_ehx026-B52","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/S0735-1097(00)01025-1","article-title":"Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. high enalapril dose study group","volume":"36","author":"Nanas","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2022102614533968100_ehx026-B53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ahj.2007.03.025","article-title":"Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial","volume":"154","author":"Dobre","year":"2007","journal-title":"Am Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/24\/1883\/46645741\/eurheartj_38_24_1883.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/24\/1883\/46645741\/eurheartj_38_24_1883.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:34:30Z","timestamp":1666784070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/38\/24\/1883\/3065510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,11]]},"references-count":53,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2017,3,11]]},"published-print":{"date-parts":[[2017,6,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx026","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6,21]]},"published":{"date-parts":[[2017,3,11]]}}}